ORIC PHARMACEUTICALS, INC. (ORIC) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 25.90M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -156.14M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $25.90M | $-156.14M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | (m) | $25.38M | $-149.91M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | $25.04M | $-143.00M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | (m) | $23.96M | $-148.02M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | (m) | $23.39M | $-149.67M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | (m) | $21.81M | $-146.62M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | $20.21M | $-142.90M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | (m) | $18.93M | $-134.75M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | $17.74M | $-125.12M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | $16.57M | $-114.09M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | $15.23M | $-110.78M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | (m) | $14.43M | $-101.47M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | $13.86M | $-98.48M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | $14.13M | $-94.19M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | $14.46M | $-91.77M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | (m) | $14.83M | $-92.45M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | $14.93M | $-85.22M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | $14.05M | $-85.58M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | $12.85M | $-78.87M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | $11.04M | $-84.35M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | $9.33M | $-91.49M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | $7.50M | $-81.56M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | $5.28M | $-74.19M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | $1.09M | $-28.57M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | $469.00K | $-22.37M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |